期刊
AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE
卷 77, 期 6, 页码 289-295出版社
AMER SOC TROP MED & HYGIENE
DOI: 10.4269/ajtmh.2007.77.289
关键词
-
GlaxoSmithKline Biologicals (GSK) is committed to the development of a safe and effective malaria vaccine. Its research program in this field was initiated in 1984 and has been continuously active to this day, making it unparalleled within the vaccine industry. Although it works in partnerships with several leading organizations from the public sector, this effort has required GSK to invest major financial and human resource commitments, and its partners rely heavily con the company's global infrastructure and expertise in research, advanced clinical development, regulatory, large-scale manufacturing, and cornmercialization. Through GSK's pioneering business model and working in partnership with global vaccine funding agencies, the company is committed to seeing that, once approved, a safe and effective malaria vaccine will be available to everyone that needs it.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据